Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy

Author:

Kerns Sarah L1ORCID,Fachal Laura2ORCID,Dorling Leila3,Barnett Gillian C34,Baran Andrea5,Peterson Derick R5,Hollenberg Michelle6,Hao Ke7,Narzo Antonio Di7,Ahsen Mehmet Eren7ORCID,Pandey Gaurav7ORCID,Bentzen Søren M8ORCID,Janelsins Michelle1,Elliott Rebecca M9,Pharoah Paul D P4ORCID,Burnet Neil G9,Dearnaley David P10,Gulliford Sarah L10,Hall Emma11,Sydes Matthew R12ORCID,Aguado-Barrera Miguel E13ORCID,Gómez-Caamaño Antonio14,Carballo Ana M14,Peleteiro Paula14,Lobato-Busto Ramón15ORCID,Stock Richard16,Stone Nelson N17,Ostrer Harry18ORCID,Usmani Nawaid19,Singhal Sandeep20,Tsuji Hiroshi21,Imai Takashi21ORCID,Saito Shiro22,Eeles Rosalind23,DeRuyck Kim24,Parliament Matthew19,Dunning Alison M3ORCID,Vega Ana1325ORCID,Rosenstein Barry S26,West Catharine M L9ORCID

Affiliation:

1. Departments of Radiation Oncology and Surgery, University of Rochester Medical Center, Rochester, NY

2. Department of Oncology

3. Department of Public Health and Primary Care

4. Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

5. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY

6. Department of Computational Biology, University of Rochester, Rochester, NY

7. Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY

8. Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore

9. Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, UK

10. Academic Urooncology Unit, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

11. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK

12. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK

13. Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS & Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain

14. Department of Radiation Oncology

15. Department of Medical Physics

16. Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Department of Radiation Oncology

17. Department of Urology

18. Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Pathology and Genetics, Albert Einstein College of Medicine, Bronx, NY

19. Division of Radiation Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada

20. Department of Pathology and Cell Biology, Columbia University, New York, NY

21. National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

22. Department of Urology, National Tokyo Medical Center, Tokyo, Japan

23. Division of Genetics and Epidemiology, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

24. Departments of Basic Medical Sciences and Radiotherapy, Ghent University Hospital, Ghent, Belgium

25. Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela, Santiago de Compostela, Spain

26. Departments of Radiation Oncology & Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

Abstract

Abstract Background A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. Methods We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ancestry who underwent radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. We used grouped relative risk models to test associations with approximately 6 million genotyped or imputed variants (time to first grade 2 or higher toxicity event). Variants with two-sided Pmeta less than 5 × 10−8 were considered statistically significant. Bayesian false discovery probability provided an additional measure of confidence. Statistically significant variants were evaluated in three Japanese cohorts (n = 962). All statistical tests were two-sided. Results Meta-analysis of the European ancestry cohorts identified three genomic signals: single nucleotide polymorphism rs17055178 with rectal bleeding (Pmeta = 6.2 × 10−10), rs10969913 with decreased urinary stream (Pmeta = 2.9 × 10−10), and rs11122573 with hematuria (Pmeta = 1.8 × 10−8). Fine-scale mapping of these three regions was used to identify another independent signal (rs147121532) associated with hematuria (Pconditional = 4.7 × 10−6). Credible causal variants at these four signals lie in gene-regulatory regions, some modulating expression of nearby genes. Previously identified variants showed consistent associations (rs17599026 with increased urinary frequency, rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated Japanese cohorts. Conclusions This study increases the understanding of the architecture of common genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, and develops risk models for testing in clinical studies. Further multinational radiogenomics studies in larger cohorts are worthwhile.

Funder

US National Institutes of Health

United States Department of Defense

European Union’s Horizon 2020

Marie Sklodowska-Curie

NIH

ELucidating Loci Involved in Prostate cancer SuscEptibility

Center for Inherited Disease Research [CIDR]

Cancer Research UK

NIHR Manchester Biomedical Research Centre

EU’s 7th Framework Programme

Spanish Instituto de Salud Carlos III

European Regional Development FEDER

Autonomous Government of Galicia

NIHR Royal Marsden Hospital and Institute of Cancer Research Biomedical Research Centre

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3